{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:55:51Z","timestamp":1777679751516,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:p>The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.<\/jats:p>","DOI":"10.1310\/hpj5001-25","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T16:13:18Z","timestamp":1532448798000},"page":"025-030","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma"],"prefix":"10.1177","volume":"50","author":[{"given":"Samantha","family":"Bryant","sequence":"first","affiliation":[{"name":"Peninsula Regional Medical Center, Salisbury, Maryland. Philadelphia College of Pharmacy, University of the Sciences."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Dominic A.","family":"Solimando","sequence":"additional","affiliation":[{"name":"Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Aubrey","family":"Waddell","sequence":"additional","affiliation":[{"name":"University of Tennessee College of Pharmacy, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,1,1]]},"reference":[{"key":"bibr1-hpj5001-25","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines Multiple Myeloma. V.1.2015. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed September 8, 2014."},{"key":"bibr2-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019778"},{"key":"bibr3-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12106"},{"key":"bibr4-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"bibr5-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2232"},{"issue":"10","key":"bibr6-hpj5001-25","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos MV","year":"2010","journal-title":"Lancet Oncol"},{"key":"bibr7-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-353995"},{"key":"bibr8-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12172"},{"key":"bibr9-hpj5001-25","doi-asserted-by":"crossref","unstructured":"NiesvizkyR, FlinnIW, RifkinR,  Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: Results from all randomized patients in the community-based, phase 3b UPFRONT study [abstract 478]. Blood. 2011. http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/118\/21\/478. Accessed November 14, 2014.","DOI":"10.1182\/blood.V118.21.478.478"},{"key":"bibr10-hpj5001-25","doi-asserted-by":"crossref","unstructured":"MateosMV, RichardsonPG, ShiH,  Higher cumulative bortezomib dose results in better overall survival (OS) in patients with previously untreated multiple myeloma (MM) receiving bortezomib-melphalan-prednisone (VMP) in the phase 3 VISTA study [abstract 1968]. Proc Am Soc Hematol. 2013. http:\/\/www.bloodjournal.org\/content\/122\/21\/1968. Accessed September 8, 2014.","DOI":"10.1182\/blood.V122.21.1968.1968"},{"key":"bibr11-hpj5001-25","doi-asserted-by":"crossref","unstructured":"KimK, LeeM, KimHJ,  Observational study of VMP (bortezomib, melphalan, prednisolone) regimen for newly diagnosed Korean myeloma patients who are not eligible for transplantation [abstract 5379]. Proc Am Soc Hematol. 2013. http:\/\/www.bloodjournal.org\/content\/122\/21\/5379. Accessed September 8, 2014.","DOI":"10.1182\/blood.V122.21.5379.5379"},{"key":"bibr12-hpj5001-25","doi-asserted-by":"crossref","unstructured":"NiesvizkyR, FlinnI, RifkinRM,  Efficacy and safety of three bortezomib-based induction and maintenance regimens in previously untreated, transplant-ineligible multiple myeloma (MM) patients (Pts): Final results from the randomized, phase 3b, US community-based UPFRONT study (NCT00507416) [abstract 1966]. Proc Am Soc Hematol. 2013. http:\/\/www.bloodjournal.org\/content\/122\/21\/1966. Accessed September 8, 2014.","DOI":"10.1182\/blood.V122.21.1966.1966"},{"key":"bibr13-hpj5001-25","doi-asserted-by":"crossref","unstructured":"MateosMV, Martinez-L\u00f3pezJ, HernandezMT,  Comparison of sequential vs alternating administration of bortezomib, melphalan and prednisone (VMP) and lenalidomide plus dexamethasone (Rd) in elderly patients with newly diagnosed multiple myeloma (MM) patients: GEM2010MAS65 trial [abstract 403]. Proc Am Soc Hematol. 2013. http:\/\/www.bloodjournal.org\/content\/122\/21\/403. Accessed: September 8, 2014.","DOI":"10.1182\/blood.V122.21.403.403"},{"key":"bibr14-hpj5001-25","doi-asserted-by":"crossref","unstructured":"LaroccaA, CavalloF, MagarottoV  Reduced doseintensity subcutaneous bortezomib plus prednisone (VP) or plus cyclophosphamide (VCP) or plus melphalan (VMP) for newly diagnosed multiple myeloma patients older than 75 years of age [abstract 539]. Proc Am Soc Hematol. 2013. http:\/\/www.bloodjournal.org\/content\/122\/21\/539. Accessed September 8, 2014.","DOI":"10.1182\/blood.V122.21.539.539"},{"key":"bibr15-hpj5001-25","unstructured":"Velcade [prescribing information]. New York: Pfizer Labs; 2013. http:\/\/www.velcade.com\/files\/PDFs\/VELCADE_PRESCRIBING_INFORMATION.pdf. Accessed September 8, 2014."},{"key":"bibr16-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"bibr17-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2555-0"},{"key":"bibr18-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.103"},{"key":"bibr19-hpj5001-25","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines - Antiemesis. V.2.2014. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed September 8, 2014."},{"key":"bibr20-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.4614"},{"key":"bibr21-hpj5001-25","unstructured":"Multinational Association for Supportive Care in Cancer. MASCC\/ESMO Antiemetic Guidelines. 2013. http:\/\/www.mascc.org\/assets\/documents\/mascc_guidelines_english_2013.pdf. Accessed September 8, 2014."},{"key":"bibr22-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4451"},{"key":"bibr23-hpj5001-25","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \u2013 Myeloid Growth Factors. V.2.2014. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloid_growth.pdf. Accessed September 8, 2014."},{"key":"bibr24-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20888"},{"key":"bibr25-hpj5001-25","volume-title":"Drug Prescribing in Renal Failure","author":"Aronoff GR","year":"2007","edition":"5"},{"key":"bibr26-hpj5001-25","unstructured":"Alkeran (melphalan) tablets [US package insert]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/014691s029lbl.pdf. Accessed June 9, 2014."},{"key":"bibr27-hpj5001-25","unstructured":"Prednisone tablet [US package insert]. http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=10fe5a3b-84dc-4600-87c2-b80c97ce18cf. Accessed June 9, 2014."},{"key":"bibr28-hpj5001-25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2873"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj5001-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1310\/hpj5001-25","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj5001-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:33:23Z","timestamp":1777451603000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1310\/hpj5001-25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1310\/hpj5001-25"],"URL":"https:\/\/doi.org\/10.1310\/hpj5001-25","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}